MindMed’s latest study underscores a critical link between generalized anxiety disorder (GAD) and elevated suicidal ideation rates, highlighting an urgent need for innovative treatment solutions. With nearly half of those experiencing severe GAD symptoms reporting significant suicidal thoughts, these findings could shape the future of mental health interventions in a meaningful way.
NEW YORK–(BUSINESS WIRE)–Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellness Survey at the Psych Congress 2025. The analysis found that nearly half (48%) of respondents with severe GAD symptoms repo
Source: Original Press Release
